arrow
P

Paul Zuck

VA San Diego Healthcare System
H指数:23
被引数:1,738

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ex vivo and in vivo HIV-1 latency reversal by Mukungulu, a protein kinase C-activating African medicinal plant extract

离体和体内HIV-1潜伏期逆转由Mukungulu(一种蛋白激酶C激活剂非洲药用植物提取物)实现

MBIO
IF4.7
2025-05-140
OA
Initial productive and latent HIV infections originate in vivo by infection of resting T cells
2023-11-152
OAAI
Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1
2023-02-2211
PRE
A Phenotypic Screen Identifies Potent DPP9 Inhibitors Capable of Killing HIV-1 Infected Cells
2022-08-3118
PRE
Detecting Sources of Immune Activation and Viral Rebound in HIV Infection
2022-08-1010
OA
Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy
2020-06-1819
OAAI
Iterative Focused Screening with Biological Fingerprints Identifies Selective Asc-1 Inhibitors Distinct from Traditional High Throughput Screening
2017-01-0616
OAAI
TarO-specific inhibitors of wall teichoic acid biosynthesis restore β-lactam efficacy against methicillin-resistant staphylococci
2016-03-09105
PREAI
Maximizing Diversity from a Kinase Screen: Identification of Novel and Selective pan-Trk Inhibitors for Chronic Pain
2014-06-1964
PREAI
Discovery and X-ray Crystallographic Analysis of a Spiropiperidine Iminohydantoin Inhibitor of β-Secretase
2008-09-2462
PREAI
Identification of small molecule estrogen-related receptor α-specific antagonists and homology modeling to predict the molecular determinants as the basis for selectivity over ERRβ and ERRγ

鉴定小分子雌激素相关受体 α 特异性拮抗剂和同源建模以预测分子决定因素作为对err β 和err γ 选择性的基础

2008-08-1515
PREAI